Equities Research Analysts’ Updated EPS Estimates for March 11th (ALGS, AMRC, APP, ARTV, BNTX, BSBR, BTG, CPI, CTEC, CURY)

Equities Research Analysts’ updated eps estimates for Wednesday, March 11th:

Aligos Therapeutics (NASDAQ:ALGS) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $50.00 target price on the stock.

Ameresco (NYSE:AMRC) had its buy rating reiterated by analysts at Stifel Nicolaus. The firm currently has a $38.00 target price on the stock, up from their previous target price of $37.00.

AppLovin (NASDAQ:APP) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $700.00 target price on the stock.

Artiva Biotherapeutics (NASDAQ:ARTV) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $18.00 price target on the stock.

BioNTech (NASDAQ:BNTX) had its buy rating reissued by analysts at The Goldman Sachs Group, Inc..

BioNTech (NASDAQ:BNTX) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. The firm currently has a $171.00 price target on the stock.

Banco Santander Brasil (NYSE:BSBR) was downgraded by analysts at Wall Street Zen from a strong-buy rating to a hold rating.

BTG (LON:BTG) had its buy rating reiterated by analysts at Stifel Nicolaus. The firm currently has a GBX 160 target price on the stock.

Capita (LON:CPI) had its buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a GBX 900 target price on the stock.

ConvaTec Group (LON:CTEC) had its buy rating reissued by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a GBX 315 target price on the stock.

Currys (LON:CURY) had its buy rating reaffirmed by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 215 target price on the stock.

Day One Biopharmaceuticals (NASDAQ:DAWN) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $21.50 price target on the stock, down from their previous price target of $27.00.

ECO Animal Health Group (LON:EAH) had its buy rating reissued by analysts at Shore Capital Group Ltd.

Fiserv (NASDAQ:FISV) had its neutral rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $70.00 price target on the stock.

4imprint Group (LON:FOUR) had its buy rating reaffirmed by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 5,140 target price on the stock.

Genuit Group (LON:GEN) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a GBX 394 target price on the stock.

Genuit Group (LON:GEN) had its buy rating reiterated by analysts at Berenberg Bank. They currently have a GBX 500 target price on the stock.

Great Lakes Dredge & Dock (NASDAQ:GLDD) had its market perform rating reiterated by analysts at CJS Securities.

The Gym Group (LON:GYM) had its buy rating reaffirmed by analysts at Shore Capital Group Ltd.

Hill & Smith (LON:HILS) had its hold rating reissued by analysts at Shore Capital Group Ltd.

Honda Motor (NYSE:HMC) was downgraded by analysts at Morgan Stanley from an overweight rating to an equal weight rating.

International Personal Finance (LON:IPF) had its sell rating reissued by analysts at Shore Capital Group Ltd.

NEXT (LON:NXT) had its hold rating reaffirmed by analysts at Shore Capital Group Ltd.

One Liberty Properties (NYSE:OLP) had its buy rating reaffirmed by analysts at B. Riley Financial, Inc.. They currently have a $27.50 price target on the stock, up from their previous price target of $26.50.

Optimum Communications (NYSE:OPTU) was downgraded by analysts at Raymond James Financial, Inc. from an outperform rating to a market perform rating.

Oracle (NYSE:ORCL) had its sector perform rating reaffirmed by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $160.00 price target on the stock.

Oracle (NYSE:ORCL) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. The firm currently has a $229.00 target price on the stock.

Oxford Biomedica (LON:OXB) had its buy rating reissued by analysts at Stifel Nicolaus. The firm currently has a GBX 950 target price on the stock.

Procore Technologies (NYSE:PCOR) had its buy rating reaffirmed by analysts at BTIG Research. BTIG Research currently has a $66.00 price target on the stock.

Persimmon (LON:PSN) had its outperform rating reaffirmed by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a GBX 1,750 price target on the stock.

Persimmon (LON:PSN) had its hold rating reaffirmed by analysts at Berenberg Bank. The firm currently has a GBX 1,300 price target on the stock.

Rainbow Rare Earths (LON:RBW) had its buy rating reiterated by analysts at Stifel Nicolaus. The firm currently has a GBX 30 target price on the stock.

Rainbow Rare Earths (LON:RBW) had its buy rating reissued by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 34 price target on the stock.

Sagimet Biosciences (NASDAQ:SGMT) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $29.00 target price on the stock.

Solid Biosciences (NASDAQ:SLDB) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $14.00 target price on the stock.

Spirax-Sarco Engineering (LON:SPX) had its hold rating reaffirmed by analysts at Berenberg Bank. The firm currently has a GBX 7,350 price target on the stock.

Supermarket Income REIT (LON:SUPR) had its buy rating reaffirmed by analysts at Stifel Nicolaus. They currently have a GBX 95 price target on the stock.

Tempus AI (NASDAQ:TEM) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $75.00 price target on the stock.

Upstart (NASDAQ:UPST) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $40.00 price target on the stock.

VICI Properties (NYSE:VICI) had its neutral rating reiterated by analysts at Mizuho. Mizuho currently has a $30.00 price target on the stock.

Telefonica Brasil (NYSE:VIV) was downgraded by analysts at UBS Group AG from a buy rating to a sell rating.

Viridian Therapeutics (NASDAQ:VRDN) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $44.00 price target on the stock.

Yext (NYSE:YEXT) was downgraded by analysts at Roth Mkm from a buy rating to a neutral rating. Roth Mkm currently has $6.00 target price on the stock, down from their previous target price of $9.50.